Epax Fish Oil Formula Subject of Long-term University Affiliated Metabolic Syndrome Studies

A series of studies will be conducted through 2013 to determine the role of marine-derived DHA on health factors such as central (waist) obesity, elevated blood pressure and more.

Oct 19 2010 --- EPAX AS confirmed that its DHA-rich 1050 TG formula is currently being studied for its potential effect on metabolic syndrome and its associated conditions. BIOCLAIMS, a scientific program that supports European university researchers and is funded by the Seventh EU (European Union) Framework Programme, will oversee a series of studies conducted through 2013 to determine what role marine-derived DHA plays on health factors such as central (waist) obesity, elevated blood pressure and triglyceride levels as well as prevalence of insulin resistance (a precursor to type II diabetes).

The program’s first study has commenced under the direction of professor Aldona Dembinska-Kiec of the University of Poland, Krakow, EPAX also confirmed. Dembinska-Kiec has designed a double-blind, placebo-controlled study involving 300 patients to analyze several metabolic syndrome health markers.

“Initial studies examining DHA’s effect on metabolic syndrome have yielded promising results. We are encouraged that further inquiry will provide additional support for an increasingly taxing health condition, and we look forward to the program’s study results as they become available over the coming years, “ stated Bjorn Refsum, CEO of EPAX AS.